Escitalopram oxalate

Product sourcing details

Place of Origin
China
Packaging
vial

Supplier: hubei fangda group

Purchasing information

Minimum order
11
Lead time
15 Days

Please confirm with the supplier: Model / reference, Key specifications / compatibility, Samples, Export markets, Supply capacity.

Product Name: Escitalopram oxalate
Synonym: (S)-CITALOPRAM;1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran-carbonitrile oxalate;ESCITALOPRAM OXALATE;S-(+)-CITAPROLAM OXALATE;S-(+)-1-3-(dimethyl-amino)propyl-1-(p-fluorophenyl)-5-phthalancarbonitrileoxalate;ESCIFALOPRAMOXALATE;(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile Ethanedioate;Cipralex
CAS: 219861-08-2
MF: C22H23FN2O5
MW: 414.43
Assay: 99%
Package: 1kg/foil bag
Standard: usp Standard
MOQ: 1kg
Usage:Mainly suitable for the treatment of severe depression .

Escitalopram Oxalate Application:
Escitalopram was approved by regulatory authorities for the treatment of major depressive disorder on the basis of four placebo controlled, double-blind trials, three of which demonstrated a statistical superiority to placebo. Nonetheless, considerable controversy exists regarding the superiority of escitalopram to its predecessor citalopram. The importance of this issue follows from the greater cost of escitalopram relative to the generic mixture of isomers citalopram prior to the expiration of the escitalopram patent in 2012, which led to charges of evergreening. Accordingly, this issue has been examined in at least 10 different systematic reviews and meta analyses. The most recent of these have concluded (with caveats in some cases) that escitalopram is modestly superior to citalopram in efficacy and/or tolerability.
  • Company: hubei fangda group
  • Contact: Michael Van

hubei fangda group

Enter between 20 to 3,000 characters. English only. Characters: 0 / 3000
submiting now We do inquire for you, please wait...